drugset / Trial / NCT04071262

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

NCT04071262

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if the study drug abemaciclib in combination with other anti-cancer therapies is safe in Japanese participants with advanced cancer.

Timeline

Start
2019-12-20
Primary completion
2021-02-12
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule Oral
Background Abiraterone acetate Small molecule Oral
Background Prednisolone Other / unclassified Oral